Details

Autor(en) / Beteiligte

• Calvert, Peter
• Ding, Wern Yew
• Das, Moloy
• Tovmassian, Lilith
• Tayebjee, Muzahir H.
• Haywood, Guy
• Martin, Claire A.
• Rajappan, Kim
• Bates, Matthew G. D.
• Temple, Ian Peter
• Reichlin, Tobias
• Chen, Zhong
• Balasubramaniam, Richard N.
• Sticherling, Christian
• Ronayne, Christina
• Clarkson, Nichola
• Morgan, Maureen
• Barton, Janet
• Kemp, Ian
• Mahida, Saagar
• Gupta, Dhiraj

Titel

Cryoballoon pulmonary vein isolation as first-line treatment of typical atrial flutter: long-term outcomes of the CRAFT trial

Ist Teil von

• Journal of interventional cardiac electrophysiology, 2024-03, Vol.67 (7), p.1529-1538

Ort / Verlag

New York: Springer US

Erscheinungsjahr

2024

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Background CRAFT was an international, multicentre, randomised controlled trial across 11 sites in the United UK and Switzerland. Given the evidence that pulmonary vein triggers may be responsible for atrial flutter (AFL) as well as atrial fibrillation (AF), we hypothesised that cryoballoon pulmonary vein isolation (PVI) would provide greater symptomatic arrhythmia reduction than cavotricuspid isthmus (CTI) ablation, whilst also reducing the subsequent burden of AF. Twelve-month outcomes were previously reported. In this study, we report the extended outcomes of the CRAFT study to 36 months. Methods Patients with typical AFL and no evidence of AF were randomised 1:1 to cryoballoon PVI or radiofrequency CTI. All patients received an implantable loop recorder (ILR) for continuous cardiac rhythm monitoring. The primary outcome was time-to-symptomatic arrhythmia recurrence > 30 s. Secondary outcomes included time-to-first-AF episode ≥ 2 min. The composite safety outcome included death, stroke and procedural complications. Results A total of 113 patients were randomised to cryoballoon PVI ( n  = 54) or radiofrequency CTI ablation ( n  = 59). Ninety-one patients reconsented for extended follow-up beyond 12 months. There was no difference in the primary outcome between arms, with the primary outcome occurring in 12 PVI vs 11 CTI patients (HR 0.97; 95% CI 0.43–2.20; p  = 0.994). AF ≥ 2 min was significantly less frequent in the PVI arm, affecting 26 PVI vs 36 CTI patients (HR 0.48; 95% CI 0.29–0.79; p  = 0.004). The composite safety outcome occurred in 5 PVI and 6 CTI patients ( p  = 0.755). Conclusion Cryoballoon PVI shows similar efficacy to radiofrequency CTI ablation in reducing symptomatic arrhythmia recurrence in patients presenting with isolated typical AFL but significantly reduces the occurrence of subsequent AF. Graphical Abstract